| 2017-12-07 09:26:02|
INSY 09:26 12/07 12/07/17
Insys Therapeutics starts proof-of-concept study of epinephrine nasal spray
INSYS Therapeutics announced that it has started a proof-of-concept study of two formulations of epinephrine nasal spray for the treatment of anaphylaxis, or severe allergic reaction, with the enrollment of the first patient. This Phase 1 clinical trial is designed to establish whether intranasal administration of epinephrine is bioequivalent to the standard method of delivering the drug, which is through intramuscular injection.